AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

SGP · NASDAQ · Biotechnology

SpyGlass Pharma (SGP)

Develops sustained drug delivery for chronic eye conditions within established surgical workflows.

$28.35

At close+1.49 (+5.55%)

Watchlist

In millions of USD, except per-share figures

In millions	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Cost of revenue	0	0	0	0
Gross profit	0	0	0	0
	11	13	15	22
Research & development	8	8	8	11
	3	6	7	11
General & administrative	3	6	0	0
Other expenses	0	0	0	0
Operating income	−11	−14	−15	−22
	1	1	2	2
Interest income	1	1	2	2
Other non-operating income	0	−1	−2	0
Income before tax	−10	−13	−14	−20
Net income from continuing operations	−10	−13	−14	−20
Net income	−10	−13	−14	−20
EPS, basic	$0.00	−$0.38	−$0.69	−$0.59
EPS, diluted	$0.00	−$0.38	−$0.69	−$0.59
Weighted average shares, basic	33	33	20	33
Weighted average shares, diluted	33	33	20	33
EBITDA	−11	−12	−14	−22
Depreciation & amortization	0	0	0	0
EBIT	−11	−13	−14	−22